Pfizer on Tuesday said it does not expect the Trump administration to make major changes to vaccine policy next year even as ...

The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

Shares of the parent companies of pharmacy benefit managers fell Tuesday after President-elect Donald Trump and others ...

Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the ...

Pfizer on Tuesday forecast 2025 profits roughly in line with Wall Street expectations, offering some relief to investors ...

Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is ...

Pfizer on Tuesday forecast 2025 profit roughly in line with estimates, offering some relief to investors after the drugmaker ...

Pfizer’s financial challenges are offset by growth potential in oncology and strong dividends. Learn why PFE stock is a "Buy" ...

On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.36 which represents a slight increase of $0.59 or 2.29% from the prior close of $25.77. The stock opened at $ and touched a ...

One of Pfizer's recently acquired revenue sources, Padcev, earned approval to treat newly diagnosed bladder cancer patients ...

The Vyndaqel family of drugs for the treatment of transthyretin amyloid cardiomyopathy is Pfizer’s fourth top-selling product ...